Predictive factors for the efficacy of abiraterone acetate for patients with castration-resistant prostate cancer

被引：0
|
作者：
Tokura, Yuumi [1 ]
Abe, Hideyuki [1 ]
Nishihara, Daisaku [2 ]
Mizuno, Tomoya [3 ]
Nukui, Akinori [3 ]
Kobayashi, Minoru [4 ]
Toyoshima, Toyoaki [2 ]
Arai, Gaku [5 ]
Yashi, Masahiro [1 ]
Okada, Hiroshi [5 ]
Kamai, Takao [1 ]
机构：
[1] Dokkyo Med Univ, Mibu, Tochigi, Japan
[2] Yuai Mem Hosp, Koga, Japan
[3] Nasu Red Cross Hosp, Otawara, Japan
[4] Utsunomiya Mem Hosp, Utsunomiya, Tochigi, Japan
[5] Dokkyo Med Univ, Koshigaya Hosp, Mibu, Tochigi, Japan
来源：
INTERNATIONAL JOURNAL OF UROLOGY | 2018年 / 25卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
UP-197
引用
收藏
页码：456 / 456
页数：1
相关论文
共 50 条
  • [1] Abiraterone acetate in castration-resistant prostate cancer
    Iacovelli, Roberto
    Palazzo, Antonella
    Procopio, Giuseppe
    Gazzaniga, Paola
    Cortesi, Enrico
    [J]. ANTI-CANCER DRUGS, 2012, 23 (03) : 247 - 254
  • [2] The impact of statin use on the efficacy of abiraterone acetate in patients with castration-resistant prostate cancer
    Harshman, Lauren C.
    Werner, Lillian
    Tripathi, Abhishek
    Wang, Xiaodong
    Maughan, Benjamin L.
    Antonarakis, Emmanuel S.
    Nakabayashi, Mari
    McKay, Rana
    Pomerantz, Mark
    Mucci, Lorelei A.
    Taplin, Mary-Ellen
    Sweeney, Christopher J.
    Lee, Gwo-Shu Mary
    Kantoff, Philip W.
    [J]. PROSTATE, 2017, 77 (13): : 1303 - 1311
  • [3] The economics of abiraterone acetate for castration-resistant prostate cancer
    Dellis, Athanasios
    Papatsoris, Athanasios G.
    [J]. EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2014, 14 (02) : 175 - 179
  • [4] Abiraterone Acetate In Metastatic Castration-Resistant Prostate Cancer
    Yang, Lily P. H.
    [J]. DRUGS, 2011, 71 (15) : 2067 - 2077
  • [5] The development of abiraterone acetate for castration-resistant prostate cancer
    Grist, Emily
    Attard, Gerhardt
    [J]. UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2015, 33 (06) : 289 - 294
  • [6] Initial experience with abiraterone acetate in patients with castration-resistant prostate cancer
    Beardo-Villar, P.
    Ledo-Cepero, M. J.
    Gavira-Moreno, R.
    Soto-Delgado, M.
    Soto-Vittalba, J.
    Alvarez-Ossorio, J. L.
    Juarez-Soto, A.
    [J]. ACTAS UROLOGICAS ESPANOLAS, 2014, 38 (05): : 339 - 345
  • [7] Efficacy of abiraterone acetate in post-docetaxel castration-resistant prostate cancer
    Vogiatzi, Paraskevi
    Claudio, Pier Paolo
    [J]. EXPERT REVIEW OF ANTICANCER THERAPY, 2010, 10 (07) : 1027 - 1030
  • [8] Safety of Abiraterone Acetate in Castration-resistant Prostate Cancer Patients With Concomitant Cardiovascular Risk Factors
    Procopio, Giuseppe
    Grassi, Paolo
    Testa, Isabella
    Verzoni, Elena
    Torri, Valter
    Salvioni, Roberto
    Valdagni, Riccardo
    de Braud, Filippo
    [J]. AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2015, 38 (05): : 479 - 482
  • [9] Niraparib and Abiraterone Acetate for Metastatic Castration-Resistant Prostate Cancer
    Chi, Kim N.
    Rathkopf, Dana
    Smith, Matthew R.
    Efstathiou, Eleni
    Attard, Gerhardt
    Olmos, David
    Lee, Ji Youl
    Small, Eric J.
    Gomes, Andrea J. Pereira De Santana
    Roubaud, Guilhem
    Saad, Marniza
    Zurawski, Bogdan
    Sakalo, Valerii
    Mason, Gary E.
    Francis, Peter
    Ms, George Wang
    Wu, Daphne
    Diorio, Brooke
    Lopez-Gitlitz, Angela
    Sandhu, Shahneen
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (18) : 3339 - +
  • [10] Erratum to Abiraterone acetate: in metastatic castration-resistant prostate cancer
    L. P. H. Yang
    [J]. Drugs, 2012, 72 (2) : 192 - 192
12345